Skip to content

Proprotein Convertase Subtilisin Kexin 9 in Rheumatoid Arthritis

The Expression of Proprotein Convertase Subtilisin Kexin 9 in Patients With Rheumatoid Arthritis Combined Atrial Fibrillation

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05191342
Enrollment
75
Registered
2022-01-13
Start date
2021-11-01
Completion date
2022-11-01
Last updated
2022-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PCSK9

Keywords

Atrial fibrillation, Rheumatoid arthritis, PCSK9

Brief summary

Rheumatoid arthritis (RA) has been proved to increase the incidence of atrial fibrillation (AF) with persistent systemic inflammation. Proprotein convertase subtilisin/kexin type 9 (PCSK9) has been found to enhance the production of pro-inflammatory cytokines. Therefore, we performed the present study to observe the expression and significance of proprotein convertase subtilisin kexin 9 (PCSK9) in patients with RA combined atrial fibrillation.

Detailed description

Atrial fibrillation (AF), the most common clinically relevant arrhythmia, is an important contributor to population morbidity and mortality. Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease, which affects approximately 1% of the population. Increasing studies demonstrated that RA had a positive correlation with increased cardiovascular diseases. Increasing studies showed that the prevalence of AF is significantly higher in RA patients than in the general population. Recently, some studies indicated that proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes inflammatory by regulating macrophage secretion of inflammatory cytokines, inducing C-reaction protein (CRP), interleukin (IL)-6, IL-8, tumor necrosis factor-α (TNF-α) and so on. However, the levels of PCSK9 in atrial fibrillation patients with rheumatoid arthritis is still unclear. Therefore, the aim of this study was to assess the expression of PCSK9 in patients with RA combined atrial fibrillation.

Interventions

DIAGNOSTIC_TESTEnzyme-linked immunosorbent assay for PCSK9

Enzyme-linked immunosorbent assay for plasma PCSK9

Sponsors

First Affiliated Hospital of Harbin Medical University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

1. Rheumatoid arthritis 2. Rheumatoid arthritis combined with AF

Exclusion criteria

1\. (1) History of hypertension, diabetes, cardiovascular disease, severe impairment of liver function, severe renal insufficiency. (2) Infectious diseases. (3) History malignant tumor. (4) Pregnant women, Lactating women. (5) Other autoimmune diseases. 2\. (1) History of hypertension, diabetes, cardiovascular disease (except for AF), severe impairment of liver function, severe renal insufficiency. (2) Infectious diseases. (3) History malignant tumor. (4) Pregnant women, Lactating women. (5) Other autoimmune diseases.

Design outcomes

Primary

MeasureTime frameDescription
The expression of PCSK9 in patients with RA combined with AFOne yearTo assess the expression and significance of plasma PCSK9 in three groups.

Countries

China

Contacts

Primary ContactMeijiao He, Doctor
hemeijiao99@sina.com86-451-85555673

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026